Zevra Therapeutics, Inc.
ZVRA
$12.28
-$0.40-3.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 53.25% | 77.54% | 183.36% | 605.36% | 481.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.25% | 77.54% | 183.36% | 605.36% | 481.73% |
| Cost of Revenue | -87.68% | 41.04% | 11.27% | -46.24% | 246.46% |
| Gross Profit | 182.46% | 80.12% | 205.38% | 1,683.41% | 1,441.32% |
| SG&A Expenses | -20.32% | 6.33% | 26.42% | 4.49% | 64.88% |
| Depreciation & Amortization | -80.45% | -80.43% | -80.45% | -79.61% | 4.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.10% | 6.31% | -9.65% | -29.29% | 35.29% |
| Operating Income | 236.08% | 264.71% | 160.42% | 115.17% | 48.19% |
| Income Before Tax | -83.36% | 2,437.19% | 162.19% | 97.06% | 487.34% |
| Income Tax Expenses | 83.81% | 484.94% | -96.74% | -- | 3,041.43% |
| Earnings from Continuing Operations | -88.28% | 1,322.65% | 134.04% | 98.36% | 474.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.28% | 1,322.65% | 134.04% | 98.36% | 474.94% |
| EBIT | 236.08% | 264.71% | 160.42% | 115.17% | 48.19% |
| EBITDA | 260.53% | 347.78% | 170.29% | 117.65% | 51.97% |
| EPS Basic | -88.55% | 1,185.17% | 131.39% | 98.60% | 360.69% |
| Normalized Basic EPS | 194.28% | 315.84% | 159.05% | 97.18% | 51.05% |
| EPS Diluted | -88.43% | 1,100.00% | 129.14% | 98.56% | 352.08% |
| Normalized Diluted EPS | 193.48% | 309.50% | 156.73% | 97.18% | 52.40% |
| Average Basic Shares Outstanding | 7.99% | 7.97% | 5.47% | 17.03% | 30.74% |
| Average Diluted Shares Outstanding | 8.90% | 11.34% | 9.78% | 17.03% | 34.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |